Document Detail


Accelerated partial-breast irradiation using proton beams: initial clinical experience.
MedLine Citation:
PMID:  17011445     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We present our initial clinical experience with proton, three-dimensional, conformal, external beam, partial-breast irradiation (3D-CPBI). METHODS AND MATERIALS: Twenty patients with Stage I breast cancer were treated with proton 3D-CPBI in a Phase I/II clinical trial. Patients were followed at 3 to 4 weeks, 6 to 8 weeks, 6 months, and every 6 months thereafter for recurrent disease, cosmetic outcome, toxicity, and patient satisfaction. RESULTS: With a median follow-up of 12 months (range, 8-22 months), no recurrent disease has been detected. Global breast cosmesis was judged by physicians to be good or excellent in 89% and 100% of cases at 6 months and 12 months, respectively. Patients rated global breast cosmesis as good or excellent in 100% of cases at both 6 and 12 months. Proton 3D-CPBI produced significant acute skin toxicity with moderate to severe skin color changes in 79% of patients at 3 to 4 weeks and moderate to severe moist desquamation in 22% of patients at 6 to 8 weeks. Telangiectasia was noted in 3 patients. Three patients reported rib tenderness in the treated area, and one rib fracture was documented. At last follow-up, 95% of patients reported total satisfaction with proton 3D-CPBI. CONCLUSIONS: Based on our study results, proton 3D-CPBI offers good-to-excellent cosmetic outcomes in 89% to 100% of patients at 6-month and 12-month follow-up and nearly universal patient satisfaction. However, proton 3D-CPBI, as used in this study, does result in significant acute skin toxicity and may potentially be associated with late skin (telangiectasia) and rib toxicity. Because of the dosimetric advantages of proton 3D-CPBI, technique modifications are being explored to improve acute skin tolerance.
Authors:
Kevin R Kozak; Barbara L Smith; Judith Adams; Ellen Kornmehl; Angela Katz; Michele Gadd; Michelle Specht; Kevin Hughes; Valeria Gioioso; Hsiao-Ming Lu; Kristina Braaten; Abram Recht; Simon N Powell; Thomas F DeLaney; Alphonse G Taghian
Related Documents :
16930935 - Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin...
1260685 - A correlation of dncb-induced delayed cutaneous hypersensitivity reactions and the cour...
17822495 - Mycosis fungoides--analysis of the duration of disease stages in patients who progress ...
18249465 - Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy wi...
22561335 - Association of her-2 copy number and her-2/cep-17 ratio with neoadjuvant taxane-contain...
20658725 - Monitoring levels of nephrotoxicity of different aminoglycosides during febrile neutrop...
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  66     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-10-02     Completed Date:  2006-11-06     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  691-8     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Breast / pathology,  radiation effects
Breast Neoplasms / psychology,  radiotherapy*,  surgery
Esthetics
Female
Follow-Up Studies
Humans
Mastectomy, Segmental
Middle Aged
Patient Satisfaction
Prospective Studies
Protons / therapeutic use*
Radiotherapy, Conformal / adverse effects,  methods*
Telangiectasis / etiology
Grant Support
ID/Acronym/Agency:
P01 CA21239/CA/NCI NIH HHS; P50 CA89393/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Protons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compar...
Next Document:  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of pha...